Nanobiotix presents initial data from esophageal cancer study
Nanobiotix has released initial data from a phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with locally advanced esophageal cancer. The treatment was well-tolerated, confirming injection feasibility and showing an 85% disease control rate.
Biotechnology company Nanobiotix has disclosed initial data from a phase 1 study assessing its investigational drug JNJ-1900 (NBTXR3) in patients with locally advanced esophageal cancer. The study results were presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).
The trial, sponsored by The University of Texas MD Anderson Cancer Center, evaluated the combination of JNJ-1900 (NBTXR3) with photon or proton chemoradiation for locally advanced esophageal adenocarcinoma. The initial findings indicate the treatment was well-tolerated in 13 patients, and intratumoral injection feasibility was confirmed.
Clinical results showed a disease control rate (DCR) of 85% (11/13) and an objective response rate (ORR) of 69% (9/13). Among these nine responders, six achieved a complete response and three achieved a partial response. Six patients who were medically indicated for surgery underwent the procedure post-treatment.
"These early results support our hypothesis that intratumoral injection of JNJ-1900 (NBTXR3) in combination with chemoradiation is both technically feasible and generally well-tolerated in patients with locally advanced esophageal adenocarcinoma," said Steven Lin, MD, PhD, Professor of Radiation Oncology at MD Anderson. Patient recruitment for the study is ongoing as planned.